Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Comparison between tacrolimus suppositories and beclomethasone suppositories for rectal inflammation, not responding to previous 5-ASA treatment.

- candidate number16287
- NTR NumberNTR4416
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR30-jan-2014
- Secondary IDs80-83600-98-10006 ZonMW
- Public TitleComparison between tacrolimus suppositories and beclomethasone suppositories for rectal inflammation, not responding to previous 5-ASA treatment.
- Scientific TitleTacrolimus suppositories versus beclomethasone suppositories for the treatment of proctitis refractory to local 5-ASA.
- hypothesisA subset of patients with ulcerative colitis have disease limited to only the rectum. Most patients will reach remission with conventional 5-ASA or corticosteroid treatments. However, there have been few studies investigating treatment options in patients who are resistant to this conventional therapy. Previous pilot studies have shown that approximately 80% of patients with refractory proctitis respond well to topical tacrolimus treatment. The aim of this study is to assess the efficacy of tacrolimus suppositores compared to beclomethasone suppositories, in a randomized controlled, double-blind fashion.
- Healt Condition(s) or Problem(s) studiedUlcerative proctitis
- Inclusion criteriaRefractory ulcerative proctitis at least 3 months before randomization, proven endoscopically (inflammation grade score 2 or higher) or histologically (grading scale 2 or higher ). Proctitis is defined as disease activity up to 20 cm beyond the anal verge. Refractory proctitis defined as a failure to at least the use of 5-asa suppositories of a maximum of 1 gram for at least 21 days and recurrent proctitis is defined as relapse within 3 months after stopping of local adequate 5-asa treatment. Endoscopy may have been performed up to 3 weeks before screening, if the endoscopy was well documented and biopsies were taken. Age 18-70 years. Written informed consent. Permitted concomitant therapy: aminosalicylates, azathioprine, 6-mercatopurine and methotrexate at stable dose for 12 weeks,
- Exclusion criteriaUse of enemas within 14 days prior to randomization Infliximab or other anti TNF treatment within 12 weeks prior to randomization Treatment with tacrolimus prior to randomization Treatment with any investigational drug within 12 weeks of randomization Treatment with any form of corticosteroids within 4 weeks of randomization Abnormal renal function (eGFR < 30 mL/min) Presence of ova, parasites, toxins or other signs of infectious agents in stool sample. Pre-existent leucopenia or thrombopenia (neutrophil count < 1,800/mm3 or platelets < 90,000/mm3) Liver function tests abnormalities (>2 ULN). Other significant medical illness that might interfere with this study: Current malignancy, immunodeficiency syndromes. Any known pre-existing medical condition that could interfere with the patient's participation in and completion of the study such as: - Pre-existing psychiatric condition, especially depression, or a history of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or suicidal attempt are excluded. Severe depression would include the following: (a) subjects who have been hospitalized for depression, (b) subjects who have received electroconvulsive therapy for depression, or (c) subjects whose depression has resulted in a prolonged absence of work and/or significant disruption of daily functions. Subjects with a history of mild depression may be considered for entry into the protocol provided that a pretreatment assessment of the subject°Įs mental status supports that the subject is clinically stable and that there is ongoing evaluation of the patient°Įs mental status during the study - CNS trauma or active seizure disorders requiring medication - Significant cardiovascular dysfunction within the past 6 months (e.g. angina, congestive heart failure, recent myocardial infarction, severe hypertension or significant arrhythmia). - Poorly controlled diabetes mellitus - Significant pulmonary dysfunction/chronic disease (e.g. chronic obstructive pulmonary disease) - Renal insufficiency (elevated serum creatinine) - Pregnancy, lactation - Substance abuse, such as alcohol (80 gram/day), I.V. drugs and inhaled drugs. If the subject has a history of substance abuse, to be considered for inclusion into the protocol, the subject must have abstained from using the abused substance for at least 2 years. Subjects receiving methadone within the past 2 years are also excluded - Positive stool culture for enteric pathogens - Any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the study.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingDouble
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-feb-2014
- planned closingdate1-sep-2015
- Target number of participants88
- InterventionsArm A: tacrolimus suppositories 2mg, once daily, for 28 days Arm B: beclomethasone suppositories 3mg, once daily, for 28 days
- Primary outcomeProportion of patients in clinical remission and endoscopic remission after 28 days of treatment. Clinical remission is defined as a decrease in CAI score °‹ 1 with rectal bleeding and stool frequency scores of 0. Endoscopic remission is defined as no mucosal friability, and a °› 1-point reduction in sigmoidoscopy score from baseline.
- Secondary outcome-Proportion of patients responding (the proportion of patients achieving clinical improvement, defined as a decrease of °›3 points from baseline in the total CAI score) and the changes in sigmoidoscopic mucosal appearance (baseline to week 4) -Safety and tolerability of tacrolimus suppositories and beclomethasone suppositories. -Quality of life (IBDQ). -Changes in histopathology from biopsies taken before and after treatment (grading scale (0_ structural changes only, 1_ chronic inflammation, 2 _ lamina propria neutrophils, 3_neutrophils in epithelium, 4 _ crypt destruction, 5 _ erosions or ulcers)).
- TimepointsTotal follow-up period per patient: 4 weeks
- Trial web site
- statusopen: patient inclusion
- Sponsor/Initiator Erasmus Medical Center, Rotterdam
- Funding
(Source(s) of Monetary or Material Support)
ZON-MW, The Netherlands Organization for Health Research and Development
- Publications-
- Brief summaryRandomized, double blind, controlled, multi-center study in Dutch university hospitals. The total follow-up period is 4 weeks.
- Main changes (audit trail)
- RECORD30-jan-2014 - 5-apr-2014

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar